How will biosimilars impact the oncology market in the US? Will physician's adopt them quickly or will they need more real world evidence to trust these new entrants? What are the challenges facing oncology practices as they move toward these presumably more affordable options? I had the chance to listen to an OBR webcast last week which provided some great insight into the future of biosimilars. I found this slide from ZS to be an good summary of where we are at...
Are you earning more or less than your hospitalist peers? Find out how many hours hospitalists work, how much time they spend with patients, and more. Are they working as hard are you? http://www.medscape.com/slideshow/compensation-2017-hospitalist-6008860?src=wnl_physrep_170722_mscpmrk_comp2017_hospitalist&uac=278505SZ&impID=1393515&faf=1
The fast passed I-O market continues to heat up. New June market share data from Symphony Health shows Keytruda gaining 4 percentage points bringing it up to a 32% share. Opdivo remains the leader but dropped from 64% to 61% share. Roche’s Tecentriq remained steady at 7% market share. This fast growing market has been the lead story since 2014 when Keytruda gain first IO approval in advanced melanoma. BMS quickly joined the fun with Opdivo shortly after with its own advanced
PhRMA released its "Pharmaceutical Pipeline Report" today. Not too surprising to see all the activity in oncology. But almost a third of the research across all phases is targeting oncology...from CAR-T therapies to PD1 combinations to gene therapy. Check out the full report at link below.